- Home
- VOR vs CLGN Comparison
VOR vs CLGN Comparison
Compare VOR & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOR
- CLGN
- Stock Information
- Founded
- VOR 2015
- CLGN 2004
- Country
- VOR United States
- CLGN Israel
- Employees
- VOR N/A
- CLGN N/A
- Industry
- VOR Biotechnology: Pharmaceutical Preparations
- CLGN Industrial Specialties
- Sector
- VOR Health Care
- CLGN Health Care
- Exchange
- VOR Nasdaq
- CLGN Nasdaq
- Market Cap
- VOR 22.1M
- CLGN 20.4M
- IPO Year
- VOR 2021
- CLGN N/A
- Fundamental
- Price
- VOR $0.24
- CLGN $1.48
- Analyst Decision
- VOR Buy
- CLGN Strong Buy
- Analyst Count
- VOR 6
- CLGN 2
- Target Price
- VOR $7.20
- CLGN $11.50
- AVG Volume (30 Days)
- VOR 1.7M
- CLGN 272.0K
- Earning Date
- VOR 08-07-2025
- CLGN 08-19-2025
- Dividend Yield
- VOR N/A
- CLGN N/A
- EPS Growth
- VOR N/A
- CLGN N/A
- EPS
- VOR N/A
- CLGN N/A
- Revenue
- VOR N/A
- CLGN $2,472,000.00
- Revenue This Year
- VOR N/A
- CLGN $2,177.67
- Revenue Next Year
- VOR N/A
- CLGN $56.52
- P/E Ratio
- VOR N/A
- CLGN N/A
- Revenue Growth
- VOR N/A
- CLGN N/A
- 52 Week Low
- VOR $0.13
- CLGN $1.40
- 52 Week High
- VOR $1.80
- CLGN $5.48
- Technical
- Relative Strength Index (RSI)
- VOR 45.84
- CLGN 41.46
- Support Level
- VOR $0.18
- CLGN $1.40
- Resistance Level
- VOR $0.23
- CLGN $1.83
- Average True Range (ATR)
- VOR 0.02
- CLGN 0.26
- MACD
- VOR 0.02
- CLGN -0.08
- Stochastic Oscillator
- VOR 60.51
- CLGN 4.11
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.